What we study
We use AI to scan vast chemical and biological spaces for compounds that target the core mechanisms of ageing — from senolytic candidates that clear damaged cells to molecules that restore mitochondrial efficiency and proteostasis.
Why it matters
Traditional drug discovery is slow, expensive, and failure-prone. Most longevity therapeutics never reach the clinic — not because the biology isn't there, but because we lack the tools to navigate it efficiently. AI changes that calculus.
Our approach
We combine large-scale molecular simulation, protein structure prediction, and multi-omics data to rank and refine candidates before any wet-lab investment. This narrows the field faster and dramatically improves the probability of hitting meaningful biological targets.